sb 202190 has been researched along with Leukemia, Pre-B-Cell in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children." | 1.34 | Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. ( Barredo, JC; Hsieh-Kinser, TT; Leclerc, GJ; Leclerc, GM; Sengupta, TK; Singh, I, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sengupta, TK | 1 |
| Leclerc, GM | 1 |
| Hsieh-Kinser, TT | 1 |
| Leclerc, GJ | 1 |
| Singh, I | 1 |
| Barredo, JC | 1 |
1 other study available for sb 202190 and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Di | 2007 |